{"id":"NCT01961609","sponsor":"Novartis Pharmaceuticals","briefTitle":"Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.","officialTitle":"Secukinumab In Patients With Moderate to Severe Active, Chronic Plaque Psoriasis Who Have Failed on TNFα antaGoNists: A Clinical Trial EvalUating Treatment REsults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10-09","primaryCompletion":"2016-07-12","completion":"2016-07-12","firstPosted":"2013-10-11","resultsPosted":"2019-03-18","lastUpdate":"2019-03-18"},"enrollment":235,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Secukinumab (AIN457)","otherNames":[]}],"arms":[{"label":"Secukinumab (AIN457) 300 mg","type":"EXPERIMENTAL"},{"label":"Secukinumab (AIN457) 150 mg","type":"EXPERIMENTAL"}],"summary":"This study was designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to anti-TNFα therapy in a United Kingdom (UK) and Republic of Ireland) specific population.","primaryOutcome":{"measure":"Percentage of Secukinumab 300 mg Participants Achieving PASI 75 at 16 Weeks","timeFrame":"16 weeks","effectByArm":[{"arm":"Secukinumab (AIN457) 300 mg","deltaMin":65.3,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":54,"countries":["Ireland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":115},"commonTop":["Nasopharyngitis","Headache","Psoriasis","Oropharyngeal pain","Cough"]}}